Group 1: Macro Economic Overview - The report indicates that the 10-year government bond futures index is fluctuating around the half-year line, consistent with previous assessments, suggesting that the weak adjustment in the stock market and the sluggish fundamentals will support high-level fluctuations in the bond market until the stock market strengthens again [4][16]. - Positive developments in US-China trade negotiations, such as the lifting of restrictions on Nvidia chips and partial easing of rare earth exports, combined with expectations of inflation stabilizing due to anti-involution policies, suggest a trend where stocks rise and bonds fall [4][16]. Group 2: Stock Market Analysis - The A-share market has seen trading volumes return above 1.5 trillion, with various sectors like banking, AI, innovative pharmaceuticals, and military industry experiencing significant rallies, reflecting a "hundred schools of thought" phenomenon [5][20]. - The report maintains that the upward trend in the index is not over, with expectations that it will surpass the high point from October 8 of the previous year, and identifies 3420 points as a strong short-term support level for the index [5][20]. - Key observation points for potential trend reversals include oil price peaks, sustained trading volume, and the stability of the RMB exchange rate [5][20][21]. Group 3: Sector Performance - The report highlights three main sectors for investment: anti-involution policies leading to recovery in sectors like photovoltaics, live pigs, and glass; significant turning points in industries such as solid-state batteries and innovative pharmaceuticals; and high-dividend sectors, particularly coal, which benefits from anti-involution policies [21][22]. - The report notes that the military industry stocks are performing well, with companies like AVIC Shenfei reaching historical highs, and the innovative pharmaceutical sector seeing a nearly 3% increase [21][22]. Group 4: Foreign Exchange Market - The onshore RMB against the USD was reported at 7.1806, showing an increase of 15 basis points from the previous day, with the offshore RMB breaking its downward trend [6][31]. - The report anticipates that the RMB will perform better than most non-USD currencies due to favorable trade negotiation outcomes compared to Europe and Japan [6][31]. Group 5: Commodity Market Insights - The Wenhua Commodity Index has completed a bottom breakout, with a recommendation to adopt a buy-on-dips strategy, particularly in anti-involution related sectors [7][35]. - The report warns investors to be cautious of strong commodities like polysilicon due to potential short squeeze risks, while suggesting that geopolitical uncertainties may lead to continued volatility in oil and related products [7][35].

生物医药 创新药动态更新 领先大市-B(维持) PD-1/VEGF/CTLA-4 三抗 CS2009：剂量爬坡耐受性良好，冷肿瘤及 PD-(L)1 经治患者中观察到抗肿瘤活性 2025 年 7 月 17 日 行业研究/行业快报 生物医药行业近一年市场表现 药物点评： 资料来源：最闻 首选股票 评级 PD-1(L1)/VEGF 双抗：多项 NSCLC III 期临床达到 PFS 终点，结直肠癌等肿瘤 一线临床获益明显 2025.7.10 芦康沙妥珠单抗：在 NSCLC、乳腺癌多 种适应症及后线 UC 临床生存获益明显 2025.7.7 分析师： 魏赟 执业登记编码：S0760522030005 邮箱：weiyun@sxzq.com 邓周宇 执业登记编码：S0760524040002 邮箱：dengzhouyu@sxzq.com 邮箱：zhangzhiyong@sxzq.com CS2009 是基石药业自研的 PD-1/VEGF/CTLA-4 三特异性抗体。CS2009 具有单价 PD-1 和 CTLA-4 结合臂以及双价 VEGFA 结合臂，通过阻断 PD-1/CTLA-4、激活T细胞及中和VEGFA，实现多维 ...

Market Performance - The A-share market continues to rise, with the Shanghai Composite Index showing a rebound trend and the Shenzhen market performing particularly strong, with almost all sectors rotating [1] - The market is reaching new highs, indicating a main upward trend, with previously mentioned strategies being validated [1] Investment Strategies - A model called "Old Duck Head" is suggested, which focuses on stocks where moving averages converge and then show signs of volume expansion, indicating potential for sudden price increases [1] - Different market phases require different models; for example, the "moving average flowering" model is particularly effective during upward trends [2] Market Outlook - Caution is advised for the next trading day due to the upcoming stock index futures settlement date, with a reminder to monitor this date [2] - Despite concerns about certain sectors like pharmaceuticals and robotics, there are still strong performances in innovative drugs and some robotics stocks [2] ETF Performance - Food and Beverage ETF (515170): Recent five-day change is +0.70%, with a PE ratio of 20.01 and a net inflow of 17.22 million [4] - Gaming ETF (159869): Recent five-day change is -3.16%, with a PE ratio of 43.26 and a net outflow of 11.49 million [4] - Cloud Computing 50 ETF (516630): Recent five-day change is +8.58%, with a PE ratio of 108.74 and a net outflow of 1.76 million [5]

【今日导读】 全球首个！我国提出的《电力储能用超级电容器》国际标准成功立项 特斯拉六座版MODEL Y L来了！分析师称看好T链核心Tier1供应商 大收购！千亿创新药巨头出手 跨境支付通香港收款行扩容至17家 全球首款该领域专用双足机器人发布 【主题详情】 全球首个！我国提出的《电力储能用超级电容器》国际标准成功立项 据媒体报道，由我国提出的《电力储能用超级电容器》国际标准提案近日在国际电工委员会（IEC）成 功立项，得到了德国、日本、芬兰等国的大力支持，是全球首个应用于电力储能领域的超级电容器国际 标准。 目前，全球储能用超级电容装机容量已突破1GW，且增长迅速，预计2030年全球储能用超级电容规模 将达到5GW～10GW。中泰证券表示，产业趋势明显，服务器或成超级电容应用新方向，此前数据中心 大多使用带电池的UPS系统，但超级电容与之相比，整体优势更强。 公司方面，东阳光专注于电极箔、电容器、超级电容器等电子材料，以及锂电池正极材料、电解液、含 氟新材料等电池材料的创新研发。公司持续推进在浙江东阳的铝电解电容器、超级电容器生产基地的建 设工作，截至目前一期项目基本建成，具备年产电容器约14亿只的生产能力 ...

Core Viewpoint - A-shares are experiencing a rebound, driven by positive external factors and a shift towards growth sectors like AI and innovative pharmaceuticals, with foreign institutions raising their economic forecasts for China [1][6][10]. Group 1: Market Performance - A-shares saw a collective rise, with the ChiNext Index increasing by nearly 2% and over 3,500 stocks gaining [2][6]. - The total trading volume in the two markets reached 1.54 trillion yuan, with sectors like military, pharmaceuticals, automotive, and semiconductors leading the gains, while precious metals, insurance, and banking sectors faced corrections [4][5]. Group 2: Sector Analysis - The AI and innovative pharmaceuticals sectors are experiencing significant growth, supported by strong narratives and event-driven catalysts [7][9]. - Recent approvals for U.S. chip exports to China, including AMD's MI308 and NVIDIA's products, indicate a major shift in U.S. policy towards AI chip exports, suggesting progress in U.S.-China trade negotiations [8]. Group 3: Foreign Investment Sentiment - At least nine U.S. and international banks have raised their GDP growth forecasts for China, with Morgan Stanley and Barclays predicting a near 5% growth, while ANZ forecasts 5.1% [10]. - Citigroup's report indicates that despite macroeconomic fluctuations, Asian markets are outperforming global counterparts, with specific targets set for major indices [10]. Group 4: Investment Strategies - The market is witnessing a shift from blue-chip stocks to technology and pharmaceutical growth stocks, indicating a potential change in investment style [5][11]. - The "new mechanism drugs" and sectors like new consumption, humanoid robots, and AI are highlighted as key investment opportunities for the second half of the year [14]. Group 5: Balanced Investment Approach - A balanced investment strategy is recommended, considering both growth and defensive stocks, especially in light of the current market dynamics and potential volatility [15].

以下文章来源于子弹财经 ，作者孟祥娜 子弹财经 . 财经新观·产业真知｜长期关注全球资本市场财经动态，深度分析IPO进程与上市企业财报，专业解读商 业模式与热点事件。 作者 | 孟祥娜 编辑 | 胡芳洁 导语：百力司康由两位海归女博士联合创立，虽未实现商业化，但核心产品临床进度领先。公司曾与 日本药企卫材深度合作，针对在研核心产品预计将获20亿美元潜在里程碑付款，但今年5月对方突然 终止合作协议，给公司的商业化前景蒙上了一层阴影。 2025年上半年，港交所迎来IPO递表热潮，企业上市热情持续高涨。 其中，生物医药领域的表现尤为抢眼。目前，脑动极光、维昇药业、映恩生物、拨康视云、恒瑞 医药等十多家生物医药企业已成功登陆港交所。 这股生物医药企业赴港上市的热潮，离不开港交所多年来对创新型企业的制度支持。自2018 年起，港交所陆续推出"18A""18C"等创新上市规则，打破了传统上市对盈利或收入的硬性 要求，为未盈利、仍处研发阶段的生物科技公司开辟了直接融资通道。 在这一背景下，6月29日，百力司康正式加入递表队列，向港交所提交上市申请。作为 创新 药企业 ，公司的针对乳腺癌、非小细胞肺癌等核心产品正处于关键研发 ...

Core Insights - The integration of AI with innovative pharmaceuticals is transforming the pharmaceutical industry by significantly enhancing research efficiency and reducing failure risks [1][2][3] - Traditional drug development takes an average of 10-15 years and costs over $2 billion, with a success rate of less than 10%, which is being disrupted by AI technologies [1][3] - China is positioned to leverage its technological, data, and policy advantages to excel in the "AI + innovative drugs" sector [1][5][6] AI Empowerment in Drug Development - AI is playing a crucial role in various stages of drug development, including target discovery, compound screening, and clinical trial design, leading to increased efficiency and reduced costs [2] - For instance, AI can analyze millions of research papers in hours to identify potential drug targets, a process that traditionally takes years [2] - AI can screen 100 million compounds in 48 hours, significantly speeding up the identification of effective drug candidates [2] Economic Benefits of AI in Pharmaceuticals - According to ARK, AI can reduce drug development costs by 85% and time by 40%, allowing patients to access urgently needed medications faster while improving pharmaceutical company performance [3] Global AI Giants in Innovative Pharmaceuticals - Major global tech companies are investing heavily in the "AI + pharmaceuticals" market, with initiatives from Alphabet, Microsoft, Amazon, and others focusing on AI applications in drug discovery and healthcare [4] - Companies like Recursion and Exscientia are utilizing AI for high-throughput drug screening and have established significant partnerships with major pharmaceutical firms [4] China's Competitive Advantages - China holds a leading position in AI technology, with over 40% of global AI patent applications, and its large-scale AI models are focused on open-source, low-cost, and high-performance solutions [5][6] - The vast medical data resources from China's 1.4 billion population, combined with high digitalization and low costs, provide a competitive edge in training precise AI models for drug development [6] Investment Opportunities in the Pharmaceutical Sector - The pharmaceutical sector has high research barriers, suggesting that investors may benefit more from diversified ETF investments rather than chasing individual stocks [7] - E Fund has a comprehensive range of pharmaceutical products, including ETFs that cover the performance of pharmaceutical assets across A-shares, Hong Kong, and US markets [7][10] - The Hang Seng Innovative Drug ETF is the only product tracking the Hang Seng Hong Kong Stock Connect Innovative Drug Index, focusing purely on core innovative drug companies [10]

访问36氪出海网站letschuhai.com，获取更多全球商业相关资讯。 今日好文 茶颜出海，不卖奶茶 零食比卖茶更赚钱？ 中国创新药「卖爆」海外！港股60%大涨，泡沫还是起点？ 出海闯世界，BD 成药企市值管理"核武器"。 "超时"的 Prime Day，商家顶压"应考" 曾经是跨境商家们"必爆窗口"的年中大促，如今更加考验商家精细化运营的真功夫。 东南亚卷疯了，中亚还没开始 这里没有过度拥挤的货架，没有泛滥的营销套路，有的是对"高性价比中国制造"的强烈需求。 热点快讯 特朗普：对日征收25%关税，或很快与印度达成协定 路透社报道，美国总统特朗普16日表示，美国可能会按照此前致信内容来执行对日本的关税税率，并可能很快与印度达成贸易协定。特朗普日前致信日本领 导人，称将从8月1日起对从日本进口商品征收25%的关税。（央视新闻） 墨加两国同意加强贸易合作应对美国关税 当地时间16日，墨西哥总统辛鲍姆表示，在美国总统特朗普对多国滥征关税的背景下，她与加拿大总理卡尼通话后同意加强墨加两国贸易合作。辛鲍姆强 调，美墨加三国贸易协议必须得到尊重。此前，特朗普曾致信包括墨西哥和加拿大在内的14国领导人，威胁这些国家如果 ...

Market Overview - The A-share market showed positive performance with the Shenzhen Composite Index and the ChiNext Index both rising over 1%, while the Shanghai Composite Index also closed in the green. The trading volume increased to 1.56 trillion, nearly 100 billion more than the previous day, indicating genuine capital inflow into the market [1]. Sector Performance - The pharmaceutical sector was particularly strong, with nearly ten stocks hitting the daily limit, including Chengdu Xian Dao and Xin Li Tai. This upward trend was not sudden, as there had been signs of support for innovative drugs from policies in the days prior, attracting capital to this sector based on solid logic rather than speculation [3]. - The printed circuit board (PCB) sector also performed well, with stocks like Man Kun Technology and Peng Ding Holdings reaching their daily limits. The strength in this sector is attributed to the recovery in demand from downstream consumer electronics and new energy, leading to increased orders and improved earnings expectations [3]. - The CPO sector showed significant gains, with stocks like Xin Yi Sheng rising over 8% and Jian Qiao Technology hitting the daily limit. This sector is closely related to AI computing power and has become active again as market sentiment improved, indicating ongoing investor interest in technology growth stocks [3]. - Conversely, the precious metals sector experienced a decline, with Shandong Gold falling over 2%. This shift can be understood as a normal rotation in the market, where increased risk appetite leads funds to move away from defensive assets like precious metals towards more elastic sectors [3]. Investment Insights - The current market dynamics reflect a logical underpinning rather than random speculation, with clear reasons for the rises in the pharmaceutical, PCB, and CPO sectors. For long-term investors, focusing on companies with solid earnings expectations and following capital flows is deemed more reliable than chasing hot trends [4].

Market Overview - The market experienced a strong upward trend throughout the day, with the ChiNext Index leading the gains. The total trading volume in the Shanghai and Shenzhen markets reached 1.54 trillion yuan, an increase of 97.3 billion yuan compared to the previous trading day. By the end of the trading session, the Shanghai Composite Index rose by 0.37%, the Shenzhen Component Index increased by 1.43%, and the ChiNext Index gained 1.76% [1] Innovation Drug Sector - The innovative drug sector led the market gains today, with the Innovative Drug ETF (517110) opening strong and ultimately closing up by 4.40% [2] - Recent positive news for the innovative drug sector includes the inclusion of the domestically developed antiviral drug Qiruisuo Wei in the World Health Organization's priority list for children's medicines, which could provide accessible and affordable treatment for children globally [4] - The National Healthcare Security Administration and the National Health Commission have issued measures to support the high-quality development of innovative drugs, including 16 specific initiatives aimed at enhancing research support, integrating innovative drugs into insurance directories, and improving clinical application [5] Performance Reports - The CXO sector has shown a positive performance trend, with companies like WuXi AppTec and Boteng Co. forecasting significant revenue growth. WuXi AppTec expects to achieve revenue of 20.799 billion yuan in the first half of 2025, a year-on-year increase of 20.64%, with adjusted net profit projected to rise by 44.43% [6] - The trend of innovation in the drug sector is expected to continue, with a focus on "innovation + internationalization" as a core direction for the pharmaceutical industry. The recovery of overseas business orders and performance in the CXO sector is also noted [6] Internationalization of Innovative Drugs - China's share of global innovative drug business development (BD) transactions has increased significantly, from 3% in 2019 to 13% in 2024, with the monetary share rising from 1% to 28%. The total amount for license-out transactions in the first half of 2025 is approaching 66 billion USD [6][7] - 2025 is anticipated to be a breakout year for Chinese innovative drugs in overseas markets, with numerous products expected to exceed transaction values of 3-5 billion USD [7] Investment Opportunities - The ongoing issuance of the Sci-Tech Innovation Drug ETF (subscription code: 589723) is gaining traction, tracking the Shanghai Stock Exchange Sci-Tech Innovation Drug Index, which focuses on leading companies in the innovative drug sector [7] - The communication ETF and ChiNext AI ETF also showed positive performance, closing up by 3.89% and 3.04% respectively [7]